IMUX — IMMUNIC, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1280776 ·
Last close
$16.46
Market Cap
$224.59M
52W High
$17.43
52W Low
$11.55
ADV30
163,623
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -33,235,000 | -32,588,000 | 189,742,000 | 186,629,000 | 38,509,000 |
| Dec 2025 | 0 | — | -23,327,000 | -19,300,000 | 24,052,000 | 15,483,000 | 30,725,000 |
| Sep 2025 | 0 | — | -25,993,000 | -25,579,000 | 40,704,000 | 35,132,000 | 30,205,000 |
| Jun 2025 | 0 | — | -27,083,000 | -26,820,000 | 61,429,000 | 55,310,000 | 27,518,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-81,331,000
Investing CF
$-116,000
Financing CF
$65,577,000
CapEx
$-116,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.89
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-641,159,000
Inventory
—
Receivables
$354,000
ST Investments
—
EBIT TTM
$-109,638,000
Pretax Income TTM
$-104,287,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -103,228,000 | -97,172,000 | 24,052,000 | 30,725,000 | — | -85,806,000 |
| Dec 2024 | 0 | -98,052,000 | -100,507,000 | 40,868,000 | 22,439,000 | — | -84,766,000 |
| Dec 2023 | 0 | -99,223,000 | -93,612,000 | 54,299,000 | 25,368,000 | — | -70,828,000 |
| Dec 2022 | 0 | -86,518,000 | -120,407,000 | 127,753,000 | 14,069,000 | — | -65,144,000 |
TTM Snapshot
Revenues TTM
$1,782,000
NetIncome TTM
$-87,653,000
OpCashFlow TTM
$0
Assets (Latest)
$40,868,000
Forward EPS
$-2.51
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $16.84 · call volume: 168 · put volume: 215
Expected Move to 2026-10-16:
±$4.95
(29.39%) —
implied range
$11.89 –
$21.79
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PEPG | PepGen Inc. | $220.94M | $3.19 | — |
| NERV | Minerva Neurosciences, Inc. | $229.67M | $4.81 | — |
| NBP | NovaBridge Biosciences | $218.58M | $1.89 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $218.12M | $4.33 | — |
| RNA | Atrium Therapeutics, Inc. | $232.98M | $13.62 | — |
News headlines (Yahoo Finance, 1h cache)
Immunic advances MS drug toward key Phase 3 data, expects results by year-end
2026-08-11 12:36 · Yahoo
Immunic appoints Elena Ridloff to board of directors
2026-08-10 20:36 · Yahoo
Immunic Appoints Elena Ridloff to Board of Directors
2026-08-10 20:05 · Yahoo
Immunic CEO on Q2 progress and Phase 3 MS trial milestones
2026-08-10 19:07 · Yahoo
Immunic to Participate in Investor Conferences in July
2026-07-09 10:30 · Yahoo
Immunic to Participate in Investor, Industry and Scientific Conferences in June
2026-06-10 10:30 · Yahoo
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
2026-05-28 14:29 · Yahoo
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
2026-05-28 10:30 · Yahoo
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
2026-05-27 13:06 · Yahoo
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
2026-05-27 10:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.